1-(2-溴吡啶-3-基)丙烷-1,3-二醇 | 1229578-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(2-溴吡啶-3-基)丙烷-1,3-二醇
• 英文名称: 1-(2-bromopyridin-3-yl)propane-1,3-diol
• 英文别名: 1-(2-Bromopyridin-3-yl)propane-1,3-diol
• CAS: 1229578-19-1
• 化学式: C₈H₁₀BrNO₂
• 分子量: 232.077
• InChiKey: QWQHTMNHBHFXIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  398.5±37.0 °C(Predicted)
• 密度：
  1.612±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-溴吡啶-3-基)丙烷-1,3-二醇 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 反应 1.5h， 生成 3,4-二氢-2H-吡喃并[2,3-b]吡啶-4-醇
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
  [FR] DÉRIVÉS D'AMIDES HÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR P2X7

  摘要：

  该发明涉及公式（I）的杂环酰胺衍生物，其中R1、R2、R3、R4、R5、X、Y和n如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。

  公开号：

  WO2013014587A1
• 作为产物：
  描述：

  ethyl 3-(2-bromopyridin-3-yl)-3-hydroxypropanoate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 1-(2-溴吡啶-3-基)丙烷-1,3-二醇
  参考文献：
  名称：

  A prodrug approach towards the development of tricyclic-based FBPase inhibitors

  摘要：

  For the purpose of reducing the strong CYP3A4 inhibitory potency of diamide prodrug 4, cyclic prodrugs of tricyclic-based FBPase inhibitors were synthesized. Extensive SAR studies led to the discovery of pyridine-containing cyclic prodrug 20, which strongly inhibited glucose production in monkey hepatocytes and also showed weak CYP3A4 inhibitory potency. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.017

文献信息

• HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
  申请人：Hilpert Kurt

  公开号：US20140163035A1

  公开（公告）日：2014-06-12

  The invention relates to heterocyclic amide derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及公式（I）的杂环酰胺衍生物，其中R1、R2、R3、R4、R5、X、Y和n如描述中所定义，其制备及其作为药用活性化合物的用途。
• Heterocyclic amide derivatives as P2X7 receptor antagonists
  申请人：Hilpert Kurt

  公开号：US09221832B2

  公开（公告）日：2015-12-29

  The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  本发明涉及公式（I）的杂环酰胺衍生物，其中R1、R2、R3、R4、R5、X、Y和n如描述中所定义，它们的制备和用作药物活性化合物。
• US9221832B2
  申请人：——

  公开号：US9221832B2

  公开（公告）日：2015-12-29
• [EN] HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'AMIDES HÉTÉROCYCLIQUES UTILISÉS COMME ANTAGONISTES DU RÉCEPTEUR P2X7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013014587A1

  公开（公告）日：2013-01-31

  The invention relates to heterocyclic amide derivatives of formula (I), wherein R1, R2, R3, R4, R5, X, Y and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  该发明涉及公式（I）的杂环酰胺衍生物，其中R1、R2、R3、R4、R5、X、Y和n如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• A prodrug approach towards the development of tricyclic-based FBPase inhibitors
  作者：Tomoharu Tsukada、Kazuhiko Tamaki、Jun Tanaka、Toshiyuki Takagi、Taishi Yoshida、Akira Okuno、Takeshi Shiiki、Mizuki Takahashi、Takahide Nishi

  DOI：10.1016/j.bmcl.2010.03.017

  日期：2010.5

  For the purpose of reducing the strong CYP3A4 inhibitory potency of diamide prodrug 4, cyclic prodrugs of tricyclic-based FBPase inhibitors were synthesized. Extensive SAR studies led to the discovery of pyridine-containing cyclic prodrug 20, which strongly inhibited glucose production in monkey hepatocytes and also showed weak CYP3A4 inhibitory potency. (C) 2010 Elsevier Ltd. All rights reserved.